Retinoid X receptors in macrophage biology

Trends in Endocrinology and Metabolism

Volumn 24, Issue 9, 2013, Pages 460-468

  Roszer, Tamás ^a   Menéndez Gutiérrez, María P ^a   Cedenilla, Marta ^a   Ricote, Mercedes ^a  

^a CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

Author keywords

Gene transcription; Inflammation; Lipid metabolism; Macrophage; Nuclear receptors

Indexed keywords

2 [4 [2 [3 CYCLOHEXYL 1 (4 CYCLOHEXYLBUTYL)UREIDO]ETHYL]PHENYLTHIO] 2 METHYLPROPIONIC ACID; 3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; 4 [(5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 2 NAPHTHYL)CARBOXAMIDO]BENZOIC ACID; [4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID; ABC TRANSPORTER; AMYLOID BETA PROTEIN; BEXAROTENE; CALCIPOTRIOL; CARBAMAZEPINE; CD36 ANTIGEN; CYTOSPORONE B; FARNESOID X RECEPTOR; FEXARAMINE; GC 24; HETERODIMER; HORMONE RECEPTOR STIMULATING AGENT; KB 141; LIVER X RECEPTOR; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PREGNANE X RECEPTOR; PROTEIN BCL 2; RETINOID X RECEPTOR; RIFAMPICIN; RITONAVIR; SOBETIROME; UNCLASSIFIED DRUG;

APOPTOSIS; ATHEROSCLEROSIS; AUTOIMMUNITY; CELL DIFFERENTIATION; CELL RENEWAL; DIMERIZATION; GENETIC TRANSCRIPTION; HEMATOPOIESIS; HUMAN; INSULIN RESISTANCE; LEUKOCYTE MIGRATION; LIPID METABOLISM; MACROPHAGE; MACROPHAGE FUNCTION; NEUTROPHIL; NONHUMAN; OXIDATION; PRIORITY JOURNAL; REVIEW;

GENE TRANSCRIPTION; INFLAMMATION; LIPID METABOLISM; MACROPHAGE; NUCLEAR RECEPTORS;

ANIMALS; HUMANS; IMMUNITY, INNATE; MACROPHAGES; RETINOID X RECEPTORS;

EID: 84883205841     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2013.04.004     Document Type: Review

References (81)

1. Lefebvre P., et al. Retinoid X receptors: common heterodimerization partners with distinct functions. Trends Endocrinol. Metab. 2010, 21:676-683.
2. Dawson M.I., Xia Z. The retinoid X receptors and their ligands. Biochim. Biophys. Acta 2012, 1821:21-56.
3. Maeng S., et al. The retinoid X receptor in a marine invertebrate chordate: evolutionary insights from urochordates. Gen. Comp. Endocrinol. 2012, 178:380-390.
4. Nunez V., et al. Retinoid X receptor alpha controls innate inflammatory responses through the up-regulation of chemokine expression. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:10626-10631.
5. Szeles L., et al. Research resource: transcriptome profiling of genes regulated by RXR and its permissive and nonpermissive partners in differentiating monocyte-derived dendritic cells. Mol. Endocrinol. 2010, 24:2218-2231.
6. Yasmin R., et al. Inhibition of mammary carcinoma cell growth by RXR is mediated by the receptor's oligomeric switch. J. Mol. Biol. 2010, 397:1121-1131.
7. Mangelsdorf D.J., et al. Nuclear receptor that identifies a novel retinoic acid response pathway. Nature 1990, 345:224-229.
8. Perez E., et al. Modulation of RXR function through ligand design. Biochim. Biophys. Acta 2012, 1821:57-69.
9. Qu L., Tang X. Bexarotene: a promising anticancer agent. Cancer Chemother. Pharmacol. 2010, 65:201-205.
10. Gronemeyer H., et al. Principles for modulation of the nuclear receptor superfamily. Nat. Rev. Drug Discov. 2004, 3:950-964.
11. Sica A., Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J. Clin. Invest. 2012, 122:787-795.
12. Glass C.K., Olefsky J.M. Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab. 2012, 15:635-645.
13. Rocha V.Z., Libby P. Obesity, inflammation, and atherosclerosis. Nat. Rev. Cardiol. 2009, 6:399-409.
14. Saijo K., et al. Regulation of microglia activation and deactivation by nuclear receptors. Glia 2013, 61:104-111.
15. Valledor A.F., Ricote M. Nuclear receptor signaling in macrophages. Biochem. Pharmacol. 2004, 67:201-212.
16. Barish G.D., et al. A Nuclear Receptor Atlas: macrophage activation. Mol. Endocrinol. 2005, 19:2466-2477.
17. Vavassori P., et al. The bile acid receptor FXR is a modulator of intestinal innate immunity. J. Immunol. 2009, 183:6251-6261.
18. Wallace K., et al. The PXR is a drug target for chronic inflammatory liver disease. J. Steroid Biochem. Mol. Biol. 2010, 120:137-148.
19. Nagy L., et al. Nuclear hormone receptors enable macrophages and dendritic cells to sense their lipid environment and shape their immune response. Physiol. Rev. 2012, 92:739-789.
20. Roszer T., et al. Autoimmune kidney disease and impaired engulfment of apoptotic cells in mice with macrophage peroxisome proliferator-activated receptor gamma or retinoid X receptor alpha deficiency. J. Immunol. 2011, 186:621-631.
21. Ricote M., et al. Normal hematopoiesis after conditional targeting of RXRalpha in murine hematopoietic stem/progenitor cells. J. Leukoc. Biol. 2006, 80:850-861.
22. Murray P.J., Wynn T.A. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 2011, 11:723-737.
23. Chute J.P., et al. Minireview: nuclear receptors, hematopoiesis, and stem cells. Mol. Endocrinol. 2010, 24:1-10.
24. Thomas M., et al. An emerging role for retinoid X receptor alpha in malignant hematopoiesis. Leuk. Res. 2012, 36:1075-1081.
25. Bar M., et al. Gene expression patterns in myelodyplasia underline the role of apoptosis and differentiation in disease initiation and progression. Transl. Oncogenomics 2008, 3:137-149.
26. Safi R., et al. Pharmacological manipulation of the RAR/RXR signaling pathway maintains the repopulating capacity of hematopoietic stem cells in culture. Mol. Endocrinol. 2009, 23:188-201.
27. Hughes P.J., et al. Vitamin D3-driven signals for myeloid cell differentiation--implications for differentiation therapy. Leuk. Res. 2010, 34:553-565.
28. Tabe Y., et al. Effects of PPARgamma ligands on leukemia. PPAR Res. 2012, 2012:483656.
29. Kazawa T., et al. Expression of liver X receptor alpha and lipid metabolism in granulocyte-macrophage colony-stimulating factor-induced human monocyte-derived macrophage. Pathol. Int. 2009, 59:152-160.
30. Zhou L., et al. Retinoid X receptor agonists inhibit phorbol-12-myristate-13-acetate (PMA)-induced differentiation of monocytic THP-1 cells into macrophages. Mol. Cell. Biochem. 2010, 335:283-289.
31. Glass C.K., Saijo K. Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat. Rev. Immunol. 2010, 10:365-376.
32. Bensinger S.J., Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 2008, 454:470-477.
33. Anand P.K., et al. Synergistic action of vitamin D and retinoic acid restricts invasion of macrophages by pathogenic mycobacteria. J. Microbiol. Immunol. Infect. 2008, 41:17-25.
34. Mencarelli A., et al. Antiatherosclerotic effect of farnesoid X receptor. Am. J. Physiol. Heart Circ. Physiol. 2009, 296:H272-H281.
35. Lefebvre P., et al. Nur77turing macrophages in atherosclerosis. Circ. Res. 2012, 110:375-377.
36. Chen Y., et al. Thyroid hormone enhances nitric oxide-mediated bacterial clearance and promotes survival after meningococcal infection. PLoS ONE 2012, 7:e41445.
37. Mukundan L., et al. PPAR-delta senses and orchestrates clearance of apoptotic cells to promote tolerance. Nat. Med. 2009, 15:1266-1272.
38. A-Gonzalez N., et al. Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity 2009, 31:245-258.
39. Rebe C., et al. Induction of transglutaminase 2 by a liver X receptor/retinoic acid receptor alpha pathway increases the clearance of apoptotic cells by human macrophages. Circ. Res. 2009, 105:393-401.
40. Menendez-Gutierrez M.P., et al. Biology and therapeutic applications of peroxisome proliferator- activated receptors. Curr. Top. Med. Chem. 2012, 12:548-584.
41. Cramer P.E., et al. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 2012, 335:1503-1506.
42. Mizwicki M.T., et al. 1α,25-dihydroxyvitamin D3 and resolvin D1 retune the balance between amyloid-β phagocytosis and inflammation in Alzheimer's disease patients. J. Alzheimers Dis. 2013, 34:155-170.
43. Tabas I., Glass C.K. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 2013, 339:166-172.
44. Franklin R.J. Neuroprotection and repair in multiple sclerosis. Nat. Rev. Neurol. 2012, 8:624-634.
45. Zhang-Gandhi C.X., Drew P.D. Liver X receptor and retinoid X receptor agonists inhibit inflammatory responses of microglia and astrocytes. J. Neuroimmunol. 2007, 183:50-59.
46. Zelcer N., et al. Attenuation of neuroinflammation and Alzheimer's disease pathology by liver X receptors. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:10601-10606.
47. Sanz M-J., et al. Retinoid X receptor agonists impair arterial mononuclear cell recruitment through peroxisome proliferator-activated receptor-γ activation. J. Immunol. 2012, 189:411-424.
48. Korf H., et al. 1,25-Dihydroxyvitamin D3 curtails the inflammatory and T cell stimulatory capacity of macrophages through an IL-10-dependent mechanism. Immunobiology 2012, 217:1292-1300.
49. Hong C., et al. Coordinate regulation of neutrophil homeostasis by liver X receptors in mice. J. Clin. Invest. 2012, 122:337-347.
50. Chao L., et al. Bone marrow NR4A expression is not a dominant factor in the development of atherosclerosis or macrophage polarization in mice. J. Lipid Res. 2013, 54:806-815.
51. Hamers A.A., et al. Bone marrow-specific deficiency of nuclear receptor Nur77 enhances atherosclerosis. Circ. Res. 2012, 110:428-438.
52. Hanna R.N., et al. NR4A1 (Nur77) deletion polarizes macrophages toward an inflammatory phenotype and increases atherosclerosis. Circ. Res. 2012, 110:416-427.
53. Chinetti-Gbaguidi G., Staels B. Lipid ligand-activated transcription factors regulating lipid storage and release in human macrophages. Biochim. Biophys. Acta 2009, 1791:486-493.
54. Rigamonti E., et al. Regulation of macrophage functions by PPAR-alpha, PPAR-gamma, and LXRs in mice and men. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1050-1059.
55. Giaginis C., et al. Correlation of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and retinoid X receptor-alpha (RXR-alpha) expression with clinical risk factors in patients with advanced carotid atherosclerosis. Med. Sci. Monit. 2011, 17:CR381-CR391.
56. Shibata N., Glass C.K. Regulation of macrophage function in inflammation and atherosclerosis. J. Lipid Res. 2009, 50(Suppl.):S277-S281.
57. Carey B., Trapnell B.C. The molecular basis of pulmonary alveolar proteinosis. Clin. Immunol. 2010, 135:223-235.
58. Liu C-C., et al. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol. 2013, 9:106-118.
59. Nishimaki-Mogami T., et al. The RXR agonists PA024 and HX630 have different abilities to activate LXR/RXR and to induce ABCA1 expression in macrophage cell lines. Biochem. Pharmacol. 2008, 76:1006-1013.
60. Bermudez B., et al. Triglyceride-rich lipoprotein regulates APOB48 receptor gene expression in human THP-1 monocytes and macrophages. J. Nutr. 2012, 142:227-232.
61. Zhou C., et al. Activation of PXR induces hypercholesterolemia in wild-type and accelerates atherosclerosis in apoE deficient mice. J. Lipid Res. 2009, 50:2004-2013.
62. Sui Y., et al. Deficiency of PXR decreases atherosclerosis in apoE-deficient mice. J. Lipid Res. 2011, 52:1652-1659.
63. Nagy Z.S., et al. Nuclear receptor mediated mechanisms of macrophage cholesterol metabolism. Mol. Cell. Endocrinol. 2013, 368:85-98.
64. McMorrow J.P., Murphy E.P. Inflammation: a role for NR4A orphan nuclear receptors?. Biochem. Soc. Trans. 2011, 39:688-693.
65. Hong C., et al. LXRalpha is uniquely required for maximal reverse cholesterol transport and atheroprotection in ApoE-deficient mice. J. Lipid Res. 2012, 53:1126-1133.
66. Umetani M., Shaul P.W. 27-Hydroxycholesterol: the first identified endogenous SERM. Trends Endocrinol. Metab. 2011, 22:130-135.
67. Im S.S., Osborne T.F. Liver X receptors in atherosclerosis and inflammation. Circ. Res. 2011, 108:996-1001.
68. Hong C., et al. Constitutive activation of LXR in macrophages regulates metabolic and inflammatory gene expression: identification of ARL7 as a direct target. J. Lipid Res. 2011, 52:531-539.
69. Ayaori M., et al. Retinoic acid receptor agonists regulate expression of ATP-binding cassette transporter G1 in macrophages. Biochim. Biophys. Acta 2012, 1821:561-572.
70. Trusca V.G., et al. STAT1 interacts with RXRalpha to upregulate ApoCII gene expression in macrophages. PLoS ONE 2012, 7:e40463.
71. Calkin A.C., Tontonoz P. Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nat. Rev. Mol. Cell Biol. 2012, 13:213-224.
72. Finan B., et al. Targeted estrogen delivery reverses the metabolic syndrome. Nat. Med. 2012, 18:1847-1856.
73. Hult E.F., et al. Molecular evolution of ultraspiracle protein (USP/RXR) in insects. PLoS ONE 2011, 6:e23416.
74. Ament S.A., et al. The transcription factor ultraspiracle influences honey bee social behavior and behavior-related gene expression. PLoS Genet. 2012, 8:e1002596.
75. Tocchini-Valentini G.D., et al. Structural and functional insights into the ligand-binding domain of a nonduplicated retinoid X nuclear receptor from the invertebrate chordate amphioxus. J. Biol. Chem. 2009, 284:1938-1948.
76. Nowickyj S.M., et al. Locust retinoid X receptors: 9-cis-retinoic acid in embryos from a primitive insect. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:9540-9545.
77. Philip S., et al. Adaptive evolution of the retinoid X receptor in vertebrates. Genomics 2012, 99:81-89.
78. Cotnoir-White D., et al. Evolution of the repertoire of nuclear receptor binding sites in genomes. Mol. Cell. Endocrinol. 2011, 334:76-82.
79. Gautier E.L., et al. Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nat. Immunol. 2012, 13:1118-1128.
80. Hume D.A. Differentiation and heterogeneity in the mononuclear phagocyte system. Mucosal Immunol. 2008, 1:432-441.
81. Yona S., et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity 2013, 38:79-91.